Freestone Grove Partners LP Collegium Pharmaceutical, Inc Transaction History
Freestone Grove Partners LP
- $8.16 Trillion
- Q4 2024
A detailed history of Freestone Grove Partners LP transactions in Collegium Pharmaceutical, Inc stock. As of the latest transaction made, Freestone Grove Partners LP holds 11,141 shares of COLL stock, worth $331,444. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,141Holding current value
$331,444% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding COLL
# of Institutions
246Shares Held
37.2MCall Options Held
59.3KPut Options Held
9.5K-
Black Rock Inc. New York, NY5.79MShares$172 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.64MShares$78.5 Million1.45% of portfolio
-
Rubric Capital Management LP New York, NY2.35MShares$69.9 Million1.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.28MShares$67.9 Million0.0% of portfolio
-
Pacer Advisors, Inc. Malvern, PA2.14MShares$63.7 Million0.15% of portfolio
About COLLEGIUM PHARMACEUTICAL, INC
- Ticker COLL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 34,126,200
- Market Cap $1.02B
- Description
- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...